UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 31, 2013
|
PHARMACYCLICS, INC.
|
||
|
(Exact name of registrant as specified in its charter)
|
||
|
Delaware
|
000-26658
|
94-3148201
|
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
995 E. Arques Avenue, Sunnyvale, California
|
94085-4521
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Registrant’s telephone number, including area code: (408) 774-0330
|
|
|
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
Dr. Lori Anne Kunkel, who served as Pharmacyclics, Inc.’s (the “Company” or “Pharmacyclics”) Chief Medical Officer tendered her resignation from the Company to pursue other interests, effective August 2, 2013. In a statement, Robert W. Duggan, the Company’s Chairman of the Board and Chief Executive Officer stated:
“We thank Lori for her many contributions to Pharmacyclics, and wish Lori continued success in all her future endeavors. As CMO, she has played a meaningful role in the receipt of three Breakthrough Therapy Designations, as well as the recently submitted New Drug Application for ibrutinib.”
In connection with her resignation, the Company’s Board of Directors accelerated the vesting of options to purchase 6,250 shares of the Company’s common stock held by Dr. Kunkel.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
July 31, 2013
|
PHARMACYCLICS, INC.
|
|
|
By:
|
/s/ Joshua T. Brumm
|
|
Name: Joshua T. Brumm
|
|
|
Title: Executive Vice President, Finance
|
|